In this article

本文中

PFE

辉瑞公司

NVO

NVO

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

Smith Collection | Archive Photos | Getty Images

史密斯收藏 | 档案照片 | 盖蒂图片社

Pfizer

辉瑞

on Thursday said its experimental obesity drug, which it

周四表示，其试验性的肥胖症药物

acquired through Metsera

通过Metsera获得

, drove solid weight loss when taken once a month in a mid-stage trial.

，在中期试验中，每月服用一次，体重显著下降。

Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in the ongoing phase two study. The injection's weight loss was up to 10.5% when analyzing all patients regardless of discontinuations.

在正在进行的第二阶段研究中，肥胖或超重患者在第28周时相比安慰剂组减重达12.3%。在分析所有患者时，无论是否中断治疗，注射药物带来的减重效果高达10.5%。

The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy, which could be a major boost for Pfizer. It's trying to enter

数据提供了早期证据，证明这种注射剂可以比现有药物更不频繁地给药，而不会降低疗效，这对辉瑞来说可能是一个重大利好。辉瑞正试图进入市场。

a market dominated

一个市场主导的

by

通过

Eli Lilly

礼来公司

and

和

Novo Nordisk

诺和诺德

's weekly injections, with a strong new entrant in

每周注射，有一个强劲的新成员加入

Novo's daily pill.

诺和的每日药丸。

Pfizer plans to advance 10 phase three trials on the injection, called PF'3944, this year.

辉瑞计划今年对名为PF'3944的注射剂开展10项三期试验。

'These topline results ... reinforce the potential of PF'3944 as a monthly treatment with competitive efficacy,' said Dr. Jim List, Pfizer's chief internal medicine officer, in a release.

“这些初步结果……证实了PF'3944作为每月一次治疗的潜力，具有竞争力的疗效，”辉瑞公司首席内科医生吉姆·李斯特博士在一份声明中表示。

The trial randomized patients to gradually switch from weekly to monthly injections of Pfizer's treatment. No plateau was observed after patients transitioned to monthly dosing, the company said.

试验随机让患者逐渐从每周注射辉瑞的治疗药物改为每月注射。公司表示，在患者过渡到每月剂量后，未观察到平台期。